Clinical Trial Update: Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vorinostat with tacrolimus and methotrexate to prevent graft-versus-host disease after unrelated stem cell transplantation has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Neoplasms
• Non-neoplastic Hematologic and Lymphocytic Disorder

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tacrolimus (Tacrolimus)
• Vorinostat (vorinostat)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Graft vs Host Disease, Hematologic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2018-01-02